References
- BEVAN, D. R. and SADLER, V. M., 1992, Quinol diglucuronides are predominant conjugated metabolites found in bile of rats following intratracheal instillation of benzo[a]pyrene. Carcinogenesis, 13, 403–407.
- DIXON, R., HSIAO, J., Hsu, H.-B., SMULKOWSKI, M., CHAN, T.-M., PRAMANIK, B. and MORTON, J., 1989, Isolation of a novel morphinan 3-0-diglucuronide metabolite from dog. Pharmaceutical Research, 6,28–32.
- FOUDA, H. G., AVERY, M. and NAVETTA, K., 1993, Simultaneous hplc-radioactivity and mass spectrometry monitoring. A drug metabolism application. Paper presented at the American Society of Mass Spectrometry Conference, 29 May, San Francisco, CA.
- GRILL, H. J. and POLLOW, K., 1991, Pharmacokinetics of droloxifene and its metabolites in breast cancer patients. American Journal of Clinical Oncology, 14 (suppl. 2), s21–29.
- HAPLIN, R. A., ULm, E. H., TILL, A. E., KARI, P. H., VYAS, K. P., HUNNINGHAKE, D. B. and DUGGAN, D. E., 1993, Biotransformation of Lovastatin. Drug Metabolism and Disposition, 21,1003–1011.
- HILL, M. J., 1995, Carbohydrate metabolism. In Role of Gut Microflora in Human Toxicology and Pharmacology, edited by M. J. Hill (London: Taylor & Francis), pp. 95–104.
- JORDAN, V. C., 1995, Alternate antiestrogens and approaches to the prevention of breast cancer. Journal of Cellular Biochemistry, 22 (suppl.), 51–57.
- KE, H. Z., SIMMONS, H. A., PIRIE, C. M., CRAWFORD, D. T. and THOMPSON, D. D., 1995, Droloxifene, a new antiestrogen antagonist/agonist, prevents bone loss in ovariectomized rats. Endocrinology, 136, 2435–2441.
- LOSER, R., SEIBEL, K., Ross, W. and EPPENBERGER, U., 1985, In vivo and in vitro antiestrogenic action of 3-hydroxytamoxifen, tamoxifen and 4-hydroxytamoxifen. European Journal of Cancer and Clinical Oncology, 21, 985–990.
- POON, G. K., CHUI, Y. C., MCCAGUE, R., LONNING, P. E., FENG, R., ROWLANDS, M. G. and JARMAN, M., 1993, Analysis of phase I and phase II metabolites of tamoxifen in breast cancer patients. Drug Metabolism and Disposition, 21, 1119–1124.
- ROSS, W., OEZE, L., LösER, R. and EPPENBERGER, U., 1983, Antiestrogenic action of 3-hydroxytamoxifen in human breast cancer cell line MCF-7. Journal of the National Cancer Institute, 71, 55–59.
- SCHELINE, R. R., 1973, Metabolism of foreign compounds by gastrointestinal microorganisms. Pharmacological Reviews, 25, 451–523.
- STRAUB, K. M., RUDEWICZ, P. and GRAV1E, C., 1987, Metabolic mapping of drugs: rapid screening techniques for xenobiotic metabolites with MS/MS techniques. Xenobiotica, 17, 413–422.
- TANAKA, Y., SEKIGUCHI, M., SAWAMOTO, T., HATA, T., Esumi, Y., SuGm, S. and NINOMEYA, S., 1994, Pharmacokinetics of droloxifene in mice, rats, monkeys, premenopausal and postmenopausal patients. European Journal of Drug Metabolisnt and Pharmacokinetks, 19, 47–58.
- TESTA, B., 1995, Carbon oxidations oxidised by cytochrome P450. In Biochemistry of Redox Reactions, edited by B. Testa and J. Caldwell (London: Academic), pp. 122–163.
- VRBANAC, J. J., O'LEARY, I. A. and BACZYNSKY, J., 1992, Utility of parent-neutral loss scan screening technique: partial characterization of urinary metabolites of U-78875 in monkey urine. Biological Mass Spectrometry, 21, 517–522.